🏥 ESTA $7.6M Long Diagonal Strangle - Big Volatility Bet on Medical Device Innovator! 💰

🏥 ESTA $7.6M Long Diagonal Strangle - Big Volatility Bet on Medical Device Innovator! 💰

📅 November 25, 2025 | 🔥 Unusual Activity Detected

🎯 The Quick Take

Someone just dropped $7.6 MILLION on a massive volatility play in Establishment Labs at 10:37:18 AM today! This sophisticated long diagonal strangle combines 5,000 $90 calls expiring May 2026 with 5,000 $65 puts expiring February 2026 - all bought at the same exact time. With ESTA trading at $71.29, this trader is betting on explosive movement in either direction while the company's Motiva breast implants continue their blockbuster U.S. market share grab. Translation: Smart money expects this medical device stock to make BIG moves over the next 6 months!

---

📊 Company Overview

Establishment Labs Holdings Inc. (ESTA) is a medical technology company revolutionizing the breast implant market:
- Market Cap: $2.01 Billion
- Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Current Price: $71.29 (near 52-week high of $69.00)
- Primary Business: Design, manufacture, and market silicone-filled breast and body-shaping implants

The company achieved a transformative milestone with FDA approval of its Motiva breast implants in September 2024 - the first new breast implant approval since 2013. The U.S. commercial launch has demonstrated exceptional early traction with approximately 20% U.S. market share already achieved.

---

💰 The Option Flow Breakdown

The Tape (November 25, 2025 @ 10:37:18):

Time	Symbol	Side	Buy/Sell	Type	Expiration	Premium	Strike	Volume	OI	Size	Spot	Option Price	Option Symbol
10:37:18	ESTA	MID	BUY	CALL	2026-05-15	$4.1M	$90	5K	0	5,000	$71.29	$8.10	ESTA20260515C90
10:37:18	ESTA	MID	BUY	PUT	2026-02-20	$3.5M	$65	5K	0	5,000	$71.29	$7.00	ESTA20260220P65

🤓 What This Actually Means

This is a Long Diagonal Strangle - one of the most sophisticated volatility plays in options trading! Here's what's happening:

• 💸 Total premium paid: $7.6M ($8.10 per call + $7.00 per put × 5,000 contracts)
• 🎯 Strike spread: $25 wide ($90 call vs $65 put) with current price at $71.29
• ⏰ Time diagonal: Calls expire May 15, 2026 (171 days), puts expire February 20, 2026 (87 days)
• 📊 Size significance: 5,000 contracts on each leg represents 500,000 shares worth ~$35.6M
• 🏦 Institutional caliber: This is NOT retail money - this is hedge fund level positioning
• 🎢 Zero open interest: Brand new positions opened today, not rolling or adjusting

What's the strategy here:
The trader believes ESTA will make a massive move but doesn't know which direction. By buying both calls and puts with different expiration dates:
- 📈 If stock explodes higher: The May $90 calls profit massively (currently $18.71 out-of-the-money)
- 📉 If stock crashes: The February $65 puts profit big (currently $6.29 out-of-the-money)
- 🎯 Breakeven points: Need stock to move beyond $16.10 on upside (to ~$161 based on strategy math) or down $14.55 on downside (to ~-$14.55 based on strategy math)
- ⚠️ Max loss: $7.6M if stock stays completely flat and both options expire worthless

Why diagonal instead of standard strangle:
Different expiration dates provide flexibility. The shorter-dated February puts can profit from near-term downside volatility, while the longer-dated May calls capture potential multi-month upside momentum. This structure also allows rolling or adjusting as market conditions change.

Unusual Score: 🔥🔥🔥 EXTREME - This happens maybe a few times per year for ESTA! The 5,000 contract size on each leg, combined with $7.6M total premium and simultaneous execution at 0.0 seconds apart, screams institutional positioning ahead of major catalysts.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

Establishment Labs has delivered spectacular returns, up 156% over the past year as of November 21, 2025. The stock is trading at $70.00 as of November 25, 2025, sitting just above the 52-week high of $69.00.

Key observations:
- 📈 Parabolic momentum: Massive acceleration since FDA approval in September 2024
- 💹 New all-time highs: Breaking above $69 resistance to fresh records
- 🎢 High volatility: Stock that can move 10-20% on earnings or news
- 📊 Volume spike: Increased institutional activity as U.S. launch exceeds expectations
- 🚀 Trend strength: Consistent higher highs and higher lows throughout 2025

Gamma-Based Support & Resistance Analysis

Current Price: $70.00

The gamma exposure map reveals critical price magnets and walls around current levels:

🔵 Support Levels (Put Gamma Below Price):
- $67.50 - Nearest support with 0.017B total gamma (3.6% below current)
- $65.00 - Major floor with 0.298B gamma exposure (7.1% below current) - THIS IS THE PUT STRIKE!
- $62.50 - Secondary support at 0.028B gamma
- $60.00 - Deep support with 0.290B gamma (14.3% below current)
- $57.50 - Extended floor at 0.007B gamma

🟠 Resistance Levels (Call Gamma Above Price):
- $72.50 - Immediate resistance with 0.001B gamma (3.6% above current)
- $75.00 - Secondary ceiling at 0.003B gamma (7.1% above current)
- $80.00 - Major resistance zone with 0.005B gamma (14.3% above current)

What this means for traders:
The gamma data shows ESTA has relatively light resistance overhead - most of the gamma concentration is in support levels below current price. This asymmetric profile often precedes upside breakouts because there's less dealer hedging pressure to cap rallies. Notice how the $65 put strike aligns perfectly with the second-strongest gamma support level - this trader knows exactly where the floor should hold.

Net GEX Bias: Bullish (0.635B call gamma vs 0.204B put gamma) - Overall positioning leans strongly bullish, suggesting dealers will support the stock on dips and allow runs on rallies.

Implied Move Analysis

Options market pricing for upcoming expirations:

• 📅 Monthly OPEX (Dec 19 - 24 days): ±$6.33 (±9.06%) → Range: $63.57 - $76.24
• 📅 Quarterly Triple Witch (Dec 19 - 24 days): ±$6.33 (±9.06%) → Range: $63.57 - $76.24
• 📅 Yearly LEAPS (Dec 18, 2026 - 388 days): ±$32.09 (±45.9%) → Range: $37.82 - $101.99

Translation for regular folks:
Options traders are pricing in a 9% move ($6.33) by December expiration - that's pretty wild for a $2 billion company! But look at the LEAP pricing: 46% expected move over the next year with an upper range hitting $102. That's EXACTLY the zone where smart money sees potential upside catalysts playing out.

The December range of $63.57-$76.24 shows significant two-way risk heading into year-end. This diagonal strangle is positioned for moves beyond these ranges - if ESTA breaks below $64 or above $76, this trade starts printing money.

Key insight: The $90 call strike might seem aggressive, but the LEAP implied move shows the options market is pricing in potential for $102 within a year. If ESTA continues capturing market share and beats earnings, $90 is absolutely in play by May expiration.

---

🎪 Catalysts

🔥 Already Happened (Recent Past)

Q3 2025 Earnings Beat - November 2025 📊

Establishment Labs delivered a transformative quarter with $53.8M revenue, up 33.7% year-over-year, marking several critical milestones:

• 💰 EPS: Loss of $0.38 vs consensus $0.51 loss (beat by 25.5%)
• 🎉 First-ever positive EBITDA: $1.2 million - profitability inflection point!
• 📈 Gross margins: Exceeded 70% for first time in company history
• 🇺🇸 U.S. Motiva revenue: $11.9 million with sequential growth continuing
• 📊 Market share: Achieved approximately 20% of U.S. breast augmentation market
• 🎯 Guidance raise: Management projects to "meaningfully exceed" $40M U.S. guidance

BTIG Price Target Increase - November 2025 💹

Following the stellar Q3 results, BTIG raised price target to $81 from $70, citing rapid U.S. market share gains and sustainable profitability trajectory. This $81 target is just $11 below the $90 call strike in this trade.

FDA Approval - September 26, 2024 🎉

The game-changer: Establishment Labs received U.S. FDA premarket approval for Motiva SmoothSilk breast implants:

• ✅ First new breast implant PMA approved by FDA since 2013
• 🌍 14-year global track record: Nearly 4 million devices delivered in 85+ countries
• 📊 Superior clinical data: Less than 1% rates of capsular contracture and rupture
• 🏥 Multi-center trial: Conducted at 32 U.S. centers plus 3 European centers

U.S. Commercial Launch - October 2024 🚀

Motiva implants became commercially available in the United States:

• 🔥 Overwhelming response: More than 400 plastic surgeons contacted post-announcement
• 👥 Sales expansion: Team doubled to 25 reps across U.S. within weeks
• 💰 Revenue ramp: $3.3M (Q4 2024) → $6.2M (Q1 2025) → $10.3M (Q2 2025) → $11.9M (Q3 2025)

CEO Transition - January 13, 2025 ⚖️

Founder Juan José Chacón-Quirós announced retirement effective March 1, 2025, with Peter Caldini (current President) appointed Interim CEO. Chacón-Quirós remains as board member and active advisor to surgeon community.

🚀 Upcoming Catalysts (Next 6 Months - Through May 2026)

Q4 2025 Earnings - Expected Late February/Early March 2026 📊

Based on historical patterns, Q4 2025 earnings should drop in late February or early March 2026. This falls perfectly within both option windows! Critical metrics to watch:

• 📈 Full-year 2025 revenue: Guidance range $205-210M with potential upside
• 🇺🇸 U.S. revenue: Management expects to "meaningfully exceed" $40M guidance - with Q1-Q3 at $28.4M, Q4 could deliver $15-20M
• 💰 Profitability sustainability: Can the Q3 positive EBITDA continue?
• 📊 Gross margin sustainability: Maintaining 70%+ critical for long-term model
• 🎯 2026 guidance: Will set tone for continued market share expansion

Q1 2026 Earnings - Expected Early May 2026 📊

This would hit right around the May call expiration! Q1 typically reports in early May based on company history. Key metrics:

• 🚀 Sequential growth: Can Q1 2026 exceed Q4 2025 despite seasonality?
• 📈 Annual revenue trajectory: Setting up for accelerated growth in 2026
• 🇺🇸 Market share progress: Continued gains vs Allergan and Mentor duopoly

U.S. Market Share Expansion - Ongoing Through May 2026 🇺🇸

Management articulated clear penetration strategy with strong growth expected to continue in 2026:

• 🎯 Current position: ~20% U.S. breast augmentation market share by year-end 2025
• 📈 Market dynamics: Surveyed surgeons anticipate 14% CAGR from 2025-2027
• 💰 Revenue opportunity: Continued quarterly sequential growth expected
• 🏆 Competitive advantage: First new FDA approval in 11 years provides novelty

Mia Femtech Platform Development 🤖

Three-year clinical results presented at 9th Annual World Symposium on Ergonomic Implants in October 2024:

• 💡 Digital health integration: Revolutionary femtech platform
• 📊 Clinical validation: Multi-year safety and efficacy data
• 🆕 Future revenue stream: Additional growth driver beyond Motiva core

China Market Ramp - 2026 Expansion 🇨🇳

Launch of Motiva Implants for China market in January 2024:

• 🌏 Massive TAM: World's largest potential addressable market
• 🚀 Growth potential: International revenue diversification
• ⏰ Timing: Ramp trajectory should accelerate through 2026

📅 Longer-Term Catalysts (Beyond Trade Window)

Investor Day - June 12, 2025 (Already Occurred) 🎤

Company held Investor Day providing:

• 🎯 Long-term strategic vision: Multi-year growth roadmap
• 💰 Financial targets: Profitability and margin expansion goals
• 🔬 Technology roadmap: Pipeline products and innovation strategy

Potential Label Expansions 📋

While not publicly disclosed, possible future regulatory catalysts:

• 🏥 Reconstruction indication: Expansion into post-mastectomy market
• 🆕 New configurations: Additional sizes, shapes, surface technologies
• 🛡️ Lifetime warranty: Differentiated positioning if data supports

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, and upcoming catalysts, here are the scenarios for this trade:

📈 Bull Case (40% probability)

Target: $85-$102 by May 2026

How the $90 calls print money:
- 🚀 Q4 2025 earnings crushes with U.S. revenue hitting $18-20M (vs $11.9M in Q3)
- 📊 Full-year 2025 revenue exceeds $210M high-end guidance significantly
- 💰 Multiple quarters of positive EBITDA prove profitability is sustainable, not one-time
- 🎯 2026 guidance calls for $250-260M+ revenue (20%+ growth)
- 🇺🇸 Market share expands to 25-30% as competitive response proves ineffective
- 📈 BTIG's $81 target proves conservative as momentum accelerates
- 🌍 China revenue ramp becomes material contributor in 2026
- 💹 Multiple expansion from growth story to profitable growth story

Why this scenario is realistic:
- LEAP implied move shows $102 upper range - market already pricing this possibility
- Sequential quarterly U.S. revenue: $3.3M → $6.2M → $10.3M → $11.9M shows clear acceleration
- Surgeons anticipate 14% market CAGR 2025-2027 supporting sustained growth
- First new implant approval in 11+ years creates unique positioning vs stale competition
- 70%+ gross margins support aggressive growth investment while maintaining path to profitability

Call payoff at $90: Breakeven. At $100: $10 × 5,000 = $50,000 profit. At $102: $12 × 5,000 = $60,000 profit.

🎯 Base Case (35% probability)

Target: $76-$85 range through May 2026

Most likely scenario - moderate win for strangle:
- ✅ Q4 2025 earnings solid with U.S. revenue $15-17M meeting raised expectations
- 📊 Full-year 2025 hits $207-209M (in-line with guidance)
- 💰 Profitability confirmed but not consistently positive every quarter
- 🇺🇸 Market share grows to 22-24% - steady progress but not explosive
- ⚖️ 2026 guidance conservative at $230-240M (15-18% growth)
- 📈 Stock trades in upper range of December implied move ($70-76)
- 🔄 CEO transition completed smoothly without operational disruption
- 💹 Valuation settles around 3-4x sales (reasonable for high-growth medical devices)

Why this is most probable:
- Stock already near all-time highs with much good news priced in
- Gamma resistance light but $80 level represents psychological barrier
- Competition from Allergan/Mentor duopoly will defend share aggressively
- Cash burn concerns persist until multiple profitable quarters demonstrated
- Execution risk during CEO transition

Trade outcome: Both legs could have modest value. The $65 puts expire worthless in February if stock holds $70+. The $90 calls retain some time value but don't profit significantly unless stock pushes toward $85+.

📉 Bear Case (25% probability)

Target: $55-$65 by February 2026

What could trigger the $65 puts to profit:
- 😰 Q4 2025 earnings disappoints with U.S. revenue growth stalling at $12-13M
- 📉 Profitability proves unsustainable - Q4 returns to operating losses
- 🏥 Surgeon adoption plateaus as Allergan/Mentor launch competitive response products
- 💸 Cash burn accelerates requiring dilutive financing (similar to $50M raise in November 2024)
- ⚖️ CEO transition creates operational disruption or strategic uncertainty
- 🇨🇳 China market ramp disappoints with minimal contribution
- 📊 2026 guidance underwhelms at sub-$220M (below market expectations)
- 💔 Broader market correction drags high-valuation growth stocks lower
- 🚨 Product liability concerns or adverse events emerge (industry-wide risk)
- 📉 Hindenburg Research short report gains traction

Why this scenario is possible but less likely:
- Momentum is strong with 156% gain over past year
- Q3 results demonstrated real operational progress (70% margins, positive EBITDA)
- U.S. market share gains are measurable and confirmed by independent data
- Strong gamma support at $65-$67.50 should limit downside
- Bullish net GEX bias suggests dealers will defend dips

Put payoff at $65: Breakeven on February expiration. At $60: $5 × 5,000 = $25,000 profit. At $55: $10 × 5,000 = $50,000 profit.

Important note: The diagonal structure means if stock crashes in December-January, the February $65 puts profit significantly even if stock recovers by May. The trader captures near-term downside volatility with the shorter-dated puts while maintaining May upside exposure with the calls.

---

💡 Trading Ideas

🛡️ Conservative: Wait for Post-Earnings Clarity

Play: Stay on sidelines until Q4 2025 earnings in late February/early March 2026

Why this works:
- ⏰ Stock at all-time highs with significant volatility expected
- 📊 $7.6M institutional bet suggests major move coming - let it play out first
- 💸 Implied volatility likely elevated - options expensive
- 🎯 Better entry after earnings volatility settles and direction clarifies
- 📉 Historical pattern: High-growth medical device stocks pull back post-earnings regardless of results

Action plan:
- 👀 Watch Q4 2025 earnings closely for U.S. revenue, profitability sustainability, 2026 guidance
- 🎯 Look for pullback to $65-67 gamma support for stock entry
- ✅ Confirm market share progress and competitive positioning before committing capital
- 📊 Monitor CEO transition progress and operational execution

Risk level: Minimal (cash position) | Skill level: Beginner-friendly

⚖️ Balanced: Post-Earnings Bull Put Spread

Play: After Q4 2025 earnings, sell bull put spread March 2026 expiration

Structure: Sell $70 puts, Buy $65 puts (March 20, 2026 expiration)

Why this works:
- 🎢 Earnings volatility crush makes put selling attractive
- 📊 Defined risk spread ($5 wide = $500 max risk per spread)
- 🎯 Leverages strong gamma support at $65-$67.50
- ⏰ 45+ days gives time for market share momentum to continue
- 💰 Collect premium betting stock holds above profitability inflection

Estimated P&L (adjust after seeing post-earnings pricing):
- 💰 Collect ~$1.50-2.00 credit per spread
- 📈 Max profit: $150-200 if ESTA stays above $70 at March expiration
- 📉 Max loss: $300-350 if ESTA below $65 (protected by gamma support)
- 🎯 Breakeven: ~$68-68.50

Entry timing: Wait 2-3 days post-earnings for IV to fully collapse

Risk level: Moderate (defined risk with strong support) | Skill level: Intermediate

🚀 Aggressive: Follow the Smart Money - Smaller Diagonal Strangle (HIGH RISK!)

Play: Mini version of institutional trade with tighter strikes

Structure: Buy 5-10 contracts each:
- $85 calls May 15, 2026 expiration
- $67.50 puts February 20, 2026 expiration

Why this could work:
- 🎯 Piggybacking on $7.6M institutional positioning with similar structure
- 💸 Tighter strikes ($85 vs $90 call, $67.50 vs $65 put) increase probability but cost more
- 📊 Captures same thesis: explosive volatility in either direction
- ⚡ Both earnings catalysts (Q4 2025 and Q1 2026) fall within trade window
- 🔄 Flexibility to close or roll legs independently as market evolves
- 🎢 Implied move pricing supports large moves - 9% monthly, 46% annual

Why this could blow up (SERIOUS RISKS):
- 💥 TOTAL LOSS POSSIBLE if stock stays flat in $70-75 range through May
- 😱 Time decay accelerates on both legs - need movement soon
- 🚨 Already at all-time highs - limited margin of safety
- ⚠️ CEO transition execution risk could cause trading range instead of breakout
- 📉 Options expensive due to elevated IV - paying premium for volatility
- 💰 Capital intensive: Each mini-strangle costs $1,500-2,000+ in premium

Estimated P&L (using current market pricing):
- 💰 Cost: ~$1,800-2,000 per strangle (10 strangles = $18,000-20,000 total)
- 📈 Breakeven upside: ~$105+ (20%+ move from current)
- 📉 Breakeven downside: ~$50 (30%+ move from current)
- 🎯 Max profit: Unlimited upside, substantial downside
- 💔 Max loss: ENTIRE PREMIUM if stock in $67-85 range at expirations

Risk level: EXTREME (total loss possible) | Skill level: Advanced only

⚠️ WARNING: DO NOT attempt this trade unless you:
- Have experience managing multi-leg option positions through earnings
- Can afford to lose 100% of premium invested ($18-20K for 10 contracts)
- Understand diagonal structures and can adjust/roll intelligently
- Can actively monitor and manage through February-May timeframe
- Accept this is a leveraged bet on volatility, not directional conviction

Adjustment strategies:
- If stock breaks above $80 by January: Consider taking profit on puts, hold calls
- If stock crashes to $60-65: Take profit on puts, potentially roll calls down
- If stuck in middle: May need to take loss or roll to different strikes/dates

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 💰 Profitability sustainability uncertainty: Q3 2025 marked first-ever positive EBITDA of $1.2M after years of quarterly losses. One quarter doesn't make a trend. Q4 2024 had $18.7M operating loss. Need multiple consecutive profitable quarters to prove this wasn't a one-time achievement driven by favorable mix or timing.

• 🏥 Entrenched duopoly competition: Allergan and Mentor control 80-90% of U.S. breast implant market with massive sales forces, cross-selling synergies (Botox, fillers), and decades-old surgeon relationships. Sientra received FDA approval in 2012 but only captured 13% market share after 12+ years, illustrating the challenge of displacing incumbents even with regulatory clearance.

• ⚖️ CEO transition execution risk: Founder Juan José Chacón-Quirós retired after 20 years during critical U.S. expansion phase, with only Interim CEO Peter Caldini appointed (not permanent). Leadership uncertainty during pivotal market penetration could disrupt momentum, relationships, or strategy execution.

• 💸 Cash burn and financing needs: $90.3M cash as of December 31, 2024 provides limited runway at $15-20M quarterly burn rate. Required $50M equity raise in November 2024 and drew $25M Oaktree credit facility. Absent sustained profitability, additional dilutive financing likely within 12-18 months.

• 📉 Revenue guidance credibility issues: Company cut 2024 guidance from $174-184M to $165-168M in November 2024 and missed Q2 2024 estimates. While Q3 2025 beat strongly, track record of over-promising creates risk current optimism proves excessive.

• 🚨 Product liability and safety concerns: Hindenburg Research published detailed short report questioning clinical data integrity and financial viability. While not validated, breast implant industry has faced massive litigation historically. FDA requested Allergan recall in 2019 due to BIA-ALCL lymphoma risk, showing regulatory risk persists.

• 📊 Valuation at all-time highs with limited margin of safety: Trading at $70-71 near top of 52-week range after 156% gain. Stock near consensus $68.29 average analyst target, suggesting limited upside unless company substantially exceeds already aggressive expectations. Any stumble triggers sharp multiple compression.

• 🏭 Market share gains may plateau: Initial 20% U.S. augmentation share includes pent-up demand from surgeons excited by first new approval in 11 years. As novelty wears off and Allergan/Mentor respond with competitive products or aggressive pricing, incremental share gains become harder. Maintaining 20% may prove ceiling rather than floor.

• 🇨🇳 China market uncertainty: Limited disclosure on China launch progress since January 2024 announcement. Regulatory environment, competitive dynamics (local manufacturers), and execution risk all unknown. Could prove distraction rather than material revenue contributor.

• 🎢 Elective procedure economic sensitivity: Breast augmentation is discretionary, deferrable during economic downturns. Consumer spending correlation and recession risk could impact volumes significantly. Generally not insurance-covered, limiting addressable patient population.

• ⏰ Options positioned for explosive move may not materialize: This $7.6M strangle requires stock to move substantially beyond current $70 level in either direction. If ESTA trades range-bound $65-80 through May, both legs could expire worthless. Implied volatility priced for fireworks that may not happen.

---

🎯 The Bottom Line

Real talk: A sophisticated institutional player just dropped $7.6 MILLION betting that Establishment Labs makes explosive moves over the next 3-6 months. This isn't a casual bet - it's a carefully structured diagonal strangle that profits from massive volatility in either direction. The timing is telling: positioned perfectly to capture Q4 2025 earnings (late Feb/early Mar 2026) and Q1 2026 earnings (early May 2026).

What this trade tells us:
- 🎯 Smart money expects ESTA to break out of $64-76 December implied move range dramatically
- 💰 Structure suggests uncertainty about direction but high conviction about magnitude
- ⚖️ $90 call strike aligns with LEAP implied move showing $102 possible by end 2026
- 📊 $65 put strike sits right on major gamma support - defined downside floor
- 🎢 Both earnings events within trade window = maximum catalyst exposure

If you own ESTA:
- ✅ Congratulations on 156% gain - consider trimming 25-50% to lock in profits at all-time highs
- 📊 Strong gamma support at $65-67.50 provides cushion for remaining position
- ⏰ Hold through Q4 2025 earnings only if you believe in sustained market share expansion story
- 🎯 If earnings beat on U.S. revenue acceleration and profitability confirmation, $85-90 becomes realistic 6-month target
- 🛡️ Set mental stop at $62-65 (major gamma support) to protect gains

If you're watching from sidelines:
- ⏰ Late February/Early March 2026 Q4 2025 earnings is the moment of truth - mark your calendar
- 🎯 Post-earnings pullback to $65-67 would be attractive entry (leveraging gamma support)
- 📈 Looking for confirmation of sustained profitability, 2026 guidance $250M+, and 25%+ market share trajectory
- 🚀 Catalysts are real: unprecedented market share gains (20% in first year vs Sientra's 13% after 12 years), first new FDA approval in 11 years, profitability inflection
- ⚠️ Risks are significant: CEO transition, cash burn, competition, valuation

If you're considering trading options:
- 🎯 This institutional positioning validates the volatility thesis - big moves are coming
- ⏰ Wait for Q4 2025 earnings to clarify direction before aggressive positioning
- 📊 Conservative approach: Bull put spreads after earnings leveraging $65 gamma support
- 🚨 Aggressive approach: Smaller diagonal strangle (5-10 contracts) with tighter strikes only if you can afford 100% loss
- ⚠️ Current valuation near all-time highs means timing is critical - early positioning risks getting caught in consolidation

Mark your calendar - Key dates:
- 📅 December 19, 2025 - Monthly/Quarterly OPEX with $63.57-76.24 implied range
- 📅 Late February/Early March 2026 - Q4 2025 earnings (critical for profitability sustainability)
- 📅 February 20, 2026 - Put leg expiration on institutional trade
- 📅 Early May 2026 - Q1 2026 earnings (likely just before call expiration)
- 📅 May 15, 2026 - Call leg expiration on institutional trade

Final verdict: This is a textbook "smart money volatility bet" from institutional players who see binary outcomes ahead. The $7.6M position size, sophisticated diagonal structure, and perfect timing around two earnings events signals high conviction that ESTA won't stay in the current $70 range. Either the market share story accelerates dramatically (bull case to $85-100+) or something breaks (competitive response, profitability disappointment, execution stumbles to $55-65). The middle-ground scenario looks least likely based on this positioning.

For retail traders: Don't blindly follow - understand the risks. This trade can lose 100% if stock stays flat. But if you believe in the Motiva growth story and can afford the risk, piggybacking with a smaller position after Q4 earnings clarity could offer asymmetric reward. The catalysts are real, the competitive moat is validating (20% share in first year is exceptional), and the institutional money is voting with serious capital. Just recognize you're betting on volatility, not direction.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and not financial advice. Past performance doesn't guarantee future results. The diagonal strangle strategy can result in 100% loss of premium if the stock trades range-bound. This institutional trade's size and structure reflect sophisticated risk management unavailable to most retail traders. Always do your own research and consider consulting a licensed financial advisor before trading. Medical device stocks carry additional risks including regulatory changes, product liability, and clinical outcome uncertainties.

---

About Establishment Labs Holdings Inc. (ESTA): Establishment Labs is a medical technology company with a $2.01 billion market cap, engaged in designing, manufacturing, and marketing silicone-filled breast and body-shaping implants in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.